Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omegaven + Dipeptiven is a combination used in parenteral nutrition, particularly for pediatric patients with parenteral nutrition-associated cholestasis (PNAC) or those requiring specialized intravenous nutritional support. - **Omegaven** is a fish oil-based lipid emulsion rich in omega-3 fatty acids (EPA and DHA), providing essential fatty acids and calories. It is indicated as a source of calories and fatty acids in pediatric patients with PNAC, supporting growth, development, and improvement of liver function parameters[1][3][5][6]. - **Dipeptiven** contains the dipeptide L-alanyl-L-glutamine, which serves as a stable source of glutamine for intravenous administration. Glutamine is considered conditionally essential during critical illness or stress; it supports protein synthesis, immune function, gut integrity, and nitrogen balance. This combination provides both lipid energy (from Omegaven) and amino acid supplementation (from Dipeptiven), often used together in total parenteral nutrition regimens for critically ill or malnourished patients who cannot tolerate enteral feeding[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Omegaven + Dipeptiven.